Compare Abbott Laboratories (ABT) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Charles Schwab Corporation Common Stock — how do they compare? Abbott Laboratories trades at $95.34 (market cap $166.94B), while Charles Schwab Corporation Common Stock trades at $102.35 (market cap $177.27B). The key difference: Abbott Laboratories and Charles Schwab Corporation Common Stock are close in size by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | SCHW | |
|---|---|---|
Market Cap | $166.94B | $177.27B |
Sector | Health | Financials |
52-Week High | $136.62 | $107.21 |
52-Week Low | $82.57 | $85.35 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Charles Schwab (SCHW) trades at $101.93, up 5.08% with strong technical momentum and bullish moving averages. The stock shows robust fundamentals with a 37.99% net income margin and consistent earnings beats, including Q1 2026 EPS of $1.43 exceeding expectations. Recent news highlights retail trading growth and a new prediction market venture with Cboe, supporting positive sentiment.
Outlook remains favorable with a $120.38 analyst price target implying 18% upside, though overbought RSI signals near-term caution. Key risks include interest rate sensitivity and competitive pressures. Wall Street consensus is bullish with 58% buy ratings, reflecting confidence in Schwab's revenue diversification and asset growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
